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Cardiovascular Topics
Prevalence, awareness, treatment and control of 
hypertension, diabetes and hypercholesterolaemia 
among adults in Dande municipality, Angola
João M Pedro, Miguel Brito, Henrique Barros
Abstract
Objectives: To estimate the prevalence, awareness, treatment 
and control of hypertension, diabetes and hypercholesterol-
aemia in an Angolan population aged 15 to 64 years and to 
determine relationships with sociodemographic, behavioural 
and anthropometric characteristics. 
Methods: A total of 2 354 individuals were assessed for behav-
ioural, sociodemographic and physical characteristics in a 
cross-sectional, community-based survey. Post-stratification 
survey weights were applied to obtain prevalence levels. 
Adjusted odds ratios for each variable related to the condi-
tions were calculated using logistic regression models.
Results: Overall, the prevalence of hypertension was 18.0%, 
diabetes 9.2% and hypercholesterolaemia 4.0%. Among 
hypertensive individuals, the awareness rate was 48.5%; 
15.8% were on treatment and 9.1% had their blood pressure 
controlled. Only 10.8% were aware they had diabetes, 4.5% 
were on treatment and 2.7% were controlled. The awareness 
level for hypercholesterolaemia was 4.2%, with 1.4% individu-
als on treatment and 1.4% controlled.
Conclusions: The prevalence levels of hypertension and diabe-
tes, which were higher than previous findings for the region, 
together with the observed low rates of awareness, treatment 
and control of all conditions studied, constitute an additional 
challenge to the regional health structures, which must rapidly 
adapt to the epidemiological shift occurring in this popula-
tion.
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Cardiovascular disease (CVD), a major cause of 
non-communicable diseases (NCDs), was responsible for 17.5 
million deaths worldwide in 2012, most occurring in low- and 
middle-income countries (LMIC). In Africa, the frequency 
of NCDs is rising rapidly, reflecting the combined effect of 
population growth and ageing, as well as nutritional and 
epidemiological transitions.1
A large proportion of CVD is the result of exposure to 
modifiable risk factors (tobacco and alcohol consumption, 
unhealthy diet and physical inactivity), which influence metabolic 
pathways and ultimately result in obesity, hypertension, 
diabetes or hypercholesterolaemia.1,2 Together, these known 
adverse conditions explain approximately half of CVD cases, as 
demonstrated in the MONICA project and the INTERHEART 
study.3,4 
Among the African population participating in the 
INTERHEART study, five risk factors (smoking, diabetes, 
hypertension, abdominal obesity and an elevated apolipoprotein 
B to apolipoprotein A-1 ratio) accounted for 89.2% of the 
population-attributable risk for the first myocardial infarction.5 
The same study suggested that uncontrolled major risk factors 
have a larger impact on the burden of CVD in Africa than 
elsewhere in the world.5 
If  the current trends persist, the risk of dying from NCDs 
will increase in the African region. However, this rising risk 
could be reversed by reaching the proposed targets for six 
behavioural and physiological risk factors (tobacco and alcohol 
use, salt intake, obesity and increased blood pressure and glucose 
levels) out of the nine global targets proposed by the World 
Health Organisation (WHO) in the Global Action Plan for the 
Prevention and Control of NCD 2013–2020.6,7
To follow the achievement of those goals, there is a need for 
sound and updated epidemiological data from all regions of the 
world. The majority of published studies for the African region 
are conducted at hospital services, which does not allow one 
to detect risk factors, awareness rates and prevalence of such 
conditions in the general population.8-10 To provide core data on 
established risk factors for the major NCDs within the context 
of low-resource settings, WHO designed the STEPwise approach 
to Surveillance (STEPS).11 STEPS uses a modular structure with 
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standardised questions and protocols, allowing adjustment of its 
application and appropriate comparisons across surveys.11 
In Angola, infectious disease and maternal and child health-
related problems remain the major causes of morbidity and 
mortality.12 However, an increased burden of NCDs has been 
observed, particularly CVD, which was responsible for 9% of 
adult deaths in 2013.13 Beyond general vital statistics, specific 
epidemiological information on CVD risk factors in Angola is 
based on only four local studies published after 2000: a survey 
of 667 adult students of Health Sciences in Lubango (prevalence 
of hypertension of 23.5%),14 a study conducted among 615 
active employees of the University Agostinho Neto, Luanda 
(prevalence of hypertension 45.2% and hypercholesterolaemia 
11.1%),15 1 464 participants surveyed in the Dande Health and 
Demographic Surveillance System (Dande-HDSS) catchment 
area (23% prevalence of hypertension),16 and a study of 421 
subjects from a rural community of Angola (2.8% prevalence 
of diabetes).17 
Building on the work carried out by Pires and colleagues,16 
and based on the STEPS methodology,11 this study aimed to 
expand the sample population to the 15- to 24-year-old group, 
and to estimate the prevalence, awareness, treatment and control 
of hypertension, diabetes and hypercholesterolaemia, and its 
association with sociodemographic (gender, age, education 
and area of  residence), behavioural (alcohol and tobacco 
consumption) and anthropometric [body mass index (BMI) and 
abdominal obesity] variables among 15- to 64-year-olds in the 
Dande-HDSS population.
Methods
A cross-sectional, community-based survey was conducted 
from September 2013 to March 2014 in the catchment area of 
the Dande-HDSS, located in Dande municipality of Bengo 
Province, Angola.18 A representative gender- and age-stratified 
random sample list of 3 515 individuals, aged between 15 and 
64 years, was drawn, as described previously.19 Of these, we 
were able to examine 2 484 (70.7%) individuals, 750 (21.3%) 
were unreachable and 281 (8.0%) refused to participate, thus 
approaching the predicted non-participation rate of 30%.19 
For analysis, we excluded participants with missing 
anthropometric values (n = 14) and pregnant women (n =116) 
due to the fact that anthropometric parameters vary during 
pregnancy. Therefore 2 354 individuals (67.0%) were included in 
the final analysis.
Information on age, completed years of school education, 
alcohol and tobacco consumption, and the previous 
measurement of any of the conditions under investigation, were 
collected through a structured interview conducted by trained 
interviewers, following a previously published protocol for data 
collection based on the WHO STEPS manual version 3.0.11,19
For this analysis, age was categorised into five 10-year age 
groups: 15 to 24, 25 to 34, 35 to 44, 45 to 54 and 55 to 64 
years old. Education was categorised according to the number 
of completed years of schooling: none, one to four years, five 
to nine years, and 10 years or more. Area of residence was 
classified as rural or urban, as previously described.18 Alcohol 
consumption was defined as none if  participants reported 
no alcohol consumption; occasional if  participants reported 
drinking alcohol two or less days per week; and frequent if  
drinking any alcohol three or more days per week. Current 
tobacco smokers were defined as participants who reported 
smoking at least one cigarette per day. 
Previous measurements of blood pressure, and glucose or 
cholesterol levels in the last year were requested from all 
participants. In the case of a positive answer, participants 
were questioned about their awareness of a previous diagnosis 
of hypertension, diabetes or hypercholesterolaemia made by 
a healthcare worker. Any individual was considered under 
treatment if  he/she indicated the use of a specific medication; 
a participant was considered controlled if  they had a current 
normal value.
Certified health professionals conducted all anthropometric 
and clinical measurements, as described previously.19 
Anthropometric measurements were performed with individuals 
wearing light clothing and no footwear, and an overnight fast 
was requested of all participants.
Body mass and height were measured using a digital scale 
SECA 803 (SECA United Kingdom, Birmingham, UK) and 
a portable stadiometer SECA 213 (SECA United Kingdom, 
Birmingham, UK). BMI was defined as the body mass (kg) 
divided by the square of the body height (m2), and further 
categorised according to WHO as underweight (< 18.5 kg/m2), 
normal (18.5 to 24.99 kg/m2), overweight (25.0 to 29.99 kg/m2) 
and obese (≥ 30 kg/m2).20 
Waist and hip circumferences were measured using 
circumference tape SECA 203 (SECA United Kingdom, 
Birmingham, UK). The waist-to-hip ratio was calculated as the 
circumference of the waist (cm) to that of the hips (cm), and 
abdominal obesity was defined as waist-to-hip ratio ≥ 0.9 for 
men and ≥ 0.85 for women.21 
Blood pressure was measured on the right arm with the 
automatic sphygmomanometer OMRON M6 Comfort (OMRON 
Healthcare Europe BV, Hoofddorp, The Netherlands), with the 
individual seated, and using an appropriate cuff size. Three 
readings were done at three-minute intervals. The mean value 
of the last two measurements was used to determine the blood 
pressure. Hypertension was defined as systolic blood pressure of 
≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg and/
or use of antihypertensive drugs during the previous two weeks.22 
Blood sugar was measured using a blood glucose meter 
ACCU-CHEK Aviva (Roche Diagnostic, Indianapolis, IN, 
USA) with ACCU-CHEK Aviva glucose reactive strips (Roche 
Diagnostic, Indianapolis, IN, USA). The definition of diabetes 
followed WHO diagnostic criteria of 126 mg/dl (6.9 mmol/l) 
glucose in a fasting blood sample,23 and/or use of antidiabetic 
drugs during the previous two weeks. 
Total cholesterol in the blood was measured using a point-of-
care device ACCUTREND Plus (Roche Diagnostic, Indianapolis, 
IN, USA) with ACCUTREND cholesterol reactive strips (Roche 
Diagnostic, Indianapolis, IN, USA). Hypercholesterolaemia was 
defined according to WHO diagnostic criteria for STEPS, with 
cholesterol ≥ 240 mg/dl (6.2 mmol/l) in a fasting blood sample,2,11 
and/or use of anticholesterol drugs during the previous two weeks.
All procedures performed in this study were in accordance 
with the standards of the ethics committee of the Angolan 
Ministry of Health and with the 1964 Helsinki declaration and 
its later amendments. Written informed consent was obtained 
from all individual participants included in the study (in the case 
of those under 18 years old, from their parent or legal guardian). 
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A copy of the signed consent form, as well as instructions 
regarding the fasting period and contact information, were 
delivered to each participant.
Statistical analysis
Data were double entered into a PostgreSQL® database and 
SPSS® version 22 (IBM Corp, Armonk, NY, USA) was used 
for statistical analysis. Post-stratification survey weights 
were calculated using the known gender and categorical age 
distribution of the Dande-HDSS population,17 and these were 
used in all further calculations. Descriptive data are reported 
as absolute frequencies and percentages or means and standard 
deviations (SD), as appropriate. 
To facilitate comparisons with other studies, the prevalence 
of the three conditions under study was determined for three 
age groups: 15 to 64, 18 to 64 and 25 to 64 years. Logistic 
regression models were fitted to the categorical variable of 
age because of its known effect on hypertension, diabetes and 
hypercholesterolaemia. Gender-specific adjusted odds ratios 
(OR) were estimated for each variable (age, residence, education, 
BMI, abdominal obesity, tobacco and alcohol consumption) 
related to the conditions studied. A 95% confidence interval 
(95% CI) and a significance level of p < 0.05 were set for all 
applicable determinations.
Results
The mean age of this population was 32.5 years (SD 13.6) with 
63.0% (n = 1 482) women and the majority (81.0%) living in urban 
settings. Nearly 10% had never received any formal education, 
with men having completed more school years. Overall, almost a 
quarter of participants had abdominal obesity (36.5% of women 
and 12.4% of men), 6.8% were obese (10.6% of women and 2.8% 
of men), 6.2% were smokers (2.7% of women and 10.0% of men) 
and approximately two-fifths consumed alcohol occasionally or 
frequently, with a higher proportion of frequent drinkers among 
men (24.6 vs 10.9%) (Table 1).
The prevalence of hypertension in the general population 
was 18.0%, reaching 20.0% in those over 18 years of age, and 
26.6% in those aged 25 to 64 years (Table 2). This prevalence was 
always higher among women than men, but with no statistically 
significant relationship (data not shown). 
The overall prevalence of diabetes among participants aged 
15 to 64 years was 9.2%; the prevalence among those over 18 
years old was 9.8%, and 11.9% in those aged over 25 years (Table 
2). Men had a higher OR than women for diabetes of 1.4 (95% 
CI: 1.0–1.8, data not shown).
Similar to that of hypertension and diabetes, the prevalence 
of hypercholesterolaemia was higher in the older age groups, 
with an estimated 5.5% in participants aged 25 to 64 years, and 
a lower prevalence of 4.0% in the overall population (Table 2). 
Women had an OR of 2.3 (95% CI: 1.3–4.0, data not show) for 
hypercholesterolaemia. 
Only five participants (0.2%; 95% CI: 0.1–0.4, data not shown) 
presented all three conditions, but 22.0% (95% CI: 18.4–26.2, 
data not shown) of hypertensive participants had an associated 
condition, as did 37.2% (95% CI: 31.1–43.7, data not shown) 
of participants with diabetes and 47.9% (95% CI: 36.7–59.3, 
data not shown) of those with hypercholesterolaemia. The most 
common associations were hypertension and diabetes, present in 
71 individuals (3.0%; 95% CI: 2.4–3.7, data not shown). 
The prevalence of hypertension was higher in rural areas (26.9 
vs 15.9% in urban areas) for both genders. Individuals with lower 
levels of education had a higher prevalence of hypertension, 
with women with no formal education presenting an OR for 
hypertension of 4.3 (Table 3). 
Table 1. Socio-demographic, anthropometric and behavioral 
characteristics of the population (Caxito, 2016)
Age (years) (n = 2 354)
All participants 
(n = 2 354)
Female
(n = 1 222)
Male 
(n = 1 132)
% (95% CI)* % (95% CI)* % (95% CI)*
15–24 36.2 (34.3–38.1) 30.1 (27.6–32.7) 42.7 (39.9–45.6)
25–34 25.9 (24.2–27.7) 25.4 (23.0–27.9) 26.5 (24.0–29.1)
35–45 16.1 (14.7–17.6) 18.7 (16.6–20.9) 13.3 (11.5–15.4)
45–54 12.6 (11.3–14.0) 15.3 (13.4–17.4) 9.7 (8.1–11.6)
55–64 9.2 (8.1–10.4) 10.6 (9.0–12.4) 7.8 (6.3–9.5)
Residence (n = 2 354)
Urban 81.0 (79.4–82.5) 81.2 (78.9–83.3) 80.8 (78.4–83.0)
Rural 19.0 (17.5–20.6) 18.8 (16.7–21.1) 19.2 (17.0–21.6)
Education (years completed) (n = 2 348)
None 9.3 (8.2–10.5) 16.6 (14.6–18.8) 1.4 (0.9–2.3)
1–4 23.1 (21.5–24.9) 34.5 (31.9–37.2) 10.9 (9.2–12.8)
5–9 42.2 (40.2–44.2) 35.7 (33.1–38.5) 49.2 (46.3–52.1)
> 10 25.4 (23.7–27.2) 13.1 (11.4–15.2) 38.5 (35.7–41.4)
BMI class (kg/m2) (n = 2 354)
Underweight (< 18.5) 11.3 (10.1–12.6) 10.2 (8.7–12.1) 12.5 (10.7–14.5)
Normal (18.5–24.9) 66.1 (64.1–67.9) 58.7 (55.9–61.4) 74.0 (71.4–76.5)
Overweight (25.0–29.9) 15.8 (14.4–17.3) 20.5 (18.4–22.9) 10.7 (9.0–12.6)
Obese (≥ 30) 6.8 (5.9–7.9) 10.6 (9.0–12.4) 2.8 (2.0–4.0)
Abdominal obesity (n = 2 354)
No 75.1 (73.3–76.8) 63.5 (60.8–66.2) 87.6 (85.6–89.4)
Yes 24.9 (23.2–26.7) 36.5 (33.8–39.2) 12.4 (10.6–14.4)
Tobacco smoking (n = 2 342)
Non-current 93.8 (92.7–94.7) 97.3 (96.2–98.1) 90.0 (88.1–91.6)
Current 6.2 (5.3–7.3) 2.7 (1.9–3.8) 10.0 (8.4–11.9)
Alcohol consumption (n = 2 335)
No consumption 63.8 (61.8–65.7) 69.5 (66.9–72.0) 57.6 (54.7–60.4)
Occasional (< 3 days per week) 18.8 (17.2–20.4) 19.6 (17.5–21.9) 17.8 (15.7–20.2)
Frequent (≥ 3 days per week) 17.5 (16.0–19.1) 10.9 (9.2–12.7) 24.6 (22.2–27.2)
*Post-stratification weights used as described in the methods section.
Table 2. Prevalence of hypertension, diabetes and hypercholesterolaemia by gender and age (Caxito, 2016)
All Participants Female Male
15–64 years 
(n = 2 354)
18–64 years 
(n = 2 100)
25–64 years 
(n = 1 503)
15–64 years 
(n = 1 222)
18–64 years 
(n = 1 116)
25–64 years 
(n = 854)
15–64 years 
(n = 1 132)
18–64 years 
(n = 984)
25–64 years 
(n = 649)
Hypertension, % (95% CI) 18.0 
(16.5–19.6)
20.0 
(18.4–21.8)
26.6 
(24.4–28.9)
20.0 
(17.8–22.3)
21.8
(19.5–24.3)
27.8 
(24.9–30.8)
15.9 
(13.9–18.1)
18.1 
(15.8–20.6)
25.1 
(21.9–28.6)
Diabetes, % (95% CI) 9.2 
(8.1–10.4)
9.8 
(8.6–11.2)
11.9 
(10.3–13.6)
8.9 
(7.4–10.6)
9.3 
(7.8–11.2)
10.8 
(8.9–13.0)
9.6 
(8.0–11.4)
10.4 
(8.7–12.5)
13.5 
(11.0–16.3)
Hypercholesterolaemia, % 
(95% CI)
4.0 
(3.2–5.0)
4.4 
(3.5–5.5)
5.5 
(4.4–6.9)
5.6 
(4.3–7.2)
6.0 
(4.7–7.8)
7.4 
(5.7–9.5)
2.0 
(1.2–3.2)
2.4 
(1.5–3.8)
2.9 
(1.8–4.8)
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Hypertension was higher among the obese (34.9% of women 
and 48.5% of men) and individuals with abdominal obesity 
(32.5% of women and 45.7% of men), with a higher OR in men 
for both conditions (Table 3). Hypertension prevalence was also 
higher among current smokers (50.0% in women and 20.4% in 
men) and frequent alcohol drinkers (28.0% in women and 24.3% 
in men). Men presented a higher OR for hypertension than 
women, related to the consumption of alcohol (Table 3). 
Residents in urban areas presented a higher prevalence of 
diabetes, with a significantly higher OR for diabetes in men. 
Participants with lower education levels had a higher prevalence 
of diabetes, but without statistical significance (Table 4). 
With regard to anthropometric variables, there was a higher 
prevalence of diabetes among obese participants (17.1% in 
women and 24.2% in men) and those with abdominal obesity 
(8.8% in women and 24.3% in men). Men with obesity (2.4 
vs underweight) and abdominal obesity (2.3 vs no abdominal 
obesity) presented higher ORs for diabetes than women (2.1 for 
obese vs underweight and 1.5 for abdominal obesity) (Table 4).
For current smokers and occasional consumers of alcohol 
the prevalence of diabetes was higher, but with no significant 
relationship (Table 4). No significant relationships were found 
with education, residence, BMI, abdominal obesity, tobacco 
smoking and alcohol consumption; however, the prevalence 
of  hypercholesterolaemia was higher among less educated 
individuals, the obese, smokers and frequent alcohol drinkers 
(Table 5).
The majority of the population (61.5%; n = 1 460) reported 
previous measures of blood pressure, and nearly half (48.5%) of 
the hypertensive participants were aware of their condition. Only 
32.5% of the aware hypertensive participants were on treatment 
and 57.7% of them had their blood pressure controlled. This 
represented only 9.1% of all hypertensive participants (Fig. 1). 
Only 7.3% (n = 172) of the population reported previous 
measurement of glycaemia, with a low awareness rate of 
10.8% among participants with diabetes in this study. Of the 
aware participants, 41.7% were receiving treatment (4.5% of 
all hyperglycaemic participants) and 60.0% had a controlled 
blood sugar level (Fig. 1). Only 2.9% (n = 68) of participants 
reported previous measures of cholesterolaemia and only 4.2% 
of individuals with hypercholesterolaemia were aware of their 
condition (Fig. 1). 
The hypertension awareness rate was higher among women 
(62.7%; 95% CI: 55.9–69.0) and older participants, without 
a difference regarding education level (Table 6). The diabetes 
awareness rate was higher among men (58.3%; 95% CI: 38.8–
75.5), older participants and those with higher education levels 
(Table 7). The hypercholesterolaemia awareness rate was higher 
Table 3. Prevalence of hypertension and relation with other factors by gender (Caxito, 2016)
Associated factor
All Participants
(n = 2 354)
Female 
(n = 1 222)
Male 
(n = 1 132)
Prevalence
% (95% CI)*
Prevalence
% (95% CI)*
Adjusted ORa, b
(95% CI)*
Prevalence
% (95% CI)*
Adjusted ORa, b
(95% CI)*
Total 18.0 (16.5–19.6) 20.0 (17.8–22.3) – 15.9 (13.9–18.1) –
Age (years)
15–24 2.8 (1.9–4.2) 1.9 (0.9–3.9) 1 3.5 (2.2–5.6) 1
25–34 12.3 (9.9–15.2) 10.6 (7.7–14.6) 6.6 (2.8–15.4) 14.3 (10.8–18.8) 4.6 (2.6–8.2)
35–44 25.6 (21.5–72.0) 26.8 (21.4–32.9) 20.3 (8.9–46.5) 23.8 (17.7-31.2) 8.7 (4.7-16.0)
45–54 38.7 (33.4–44.4) 39.6 (32.8–39.6) 36.6 (16.0–83.8) 37.3 (28.8–46.6) 16.2 (8.7–30.0)
55–64 51.6 (45.0–58.2) 53.5 (44.9–61.9) 63.4 (27.1–147.9) 48.9 (38.7–59.1) 26.4 (13.9–50.0)
Residence
Urban 15.9 (14.3–17.6) 17.6 (15.3–20.1) – 14.0 (11.9–16.4) –
Rural 26.9 (23.0–31.2) 30.0 (24.4–36.2) – 23.5 (18.4–29.6) –
Education (years completed)
None 45.4 (38.9–52.0) 45.5 (38.8–52.4) 4.3 (1.8–10.2) 46.7 (24.8–69.9) 2.0 (0.6–6.5)
1–4 24.9 (21.4–28.7) 23.3 (19.5–27.6) 2.4 (1.0–5.4) 29.8 (22.5–38.4) 0.8 (0.5–1.5)
5–9 12.7 (10.8–14.9) 10.3 (7.8–13.6) 2.2 (0.9–5.1) 14.5 (11.8–17.7) 0.9 (0.6–1.4)
> 10 10.4 (8.2–13.1) 4.4 (2.1–8.8) 1 12.6 (9.8–16.1) 1
BMI class (kg/m2)
Underweight (< 18.5) 11.0 (7.8-15.3) 12.9 (8.1-19.0) 1 9.3 (5.5-15.2) 1
Normal (18.5–24.9) 15.2 (13.5–17.1) 17.0 (14.4–19.9) 1.1 (0.6–2.1) 13.7 (11.5–16.2) 1.3 (0.7–2.5)
Overweight (25.0–29.9) 25.8 (21.6–30.5) 23.9 (19.0–29.5) 1.2 (0.6–2.3) 29.2 (21.8–37.8) 2.2 (1.1–4.7)
Obese (≥ 30) 37.3 (30.2–45.0) 34.9 (27.2–43.4) 2.0 (1.0–4.1) 48.5 (32.5–64.8) 5.1 (1.9–13.4)
Abdominal obesity
No 12.1 (10.6–13.7) 12.6 (10.5–15.2) 1 11.6 (9.7–13.7) 1
Yes 35.7 (31.9–39.6) 32.5 (28.3–37.0) 1.6 (1.2-2.3) 45.7 (37.7–54.0) 2.8 (1.8–4.3)
Tobacco smoking
Non-current 17.3 (15.8–18.9) 18.9 (16.7–21.2) – 15.5 (13.4–17.8) –
Current 26.7 (20.2–34.4) 50.0 (34.1–65.9) – 20.4 (14.0–28.7) –
Alcohol consumption
No consumpion 14.2 (12.6–16.1) 18.1 (15.7–20.9) 1 9.1 (7.2–11.6) 1
Occasional (< 3 days per week) 23.5 (19.8–23.5) 21.4 (16.7–27.1) 0.9 (0.6–1.4) 26.0 (20.4–32.5) 2.5 (1.6–4.0)
Frequent (≥ 3 days per week) 25.5 (21.5–25.5) 28.0 (21.1–36.2) 1.7 (1.1–2.7) 24.3 (19.6–29.7) 2.5 (1.7–3.9)
*Post-stratification weights used as described in the methods section.
aAdjusted for age (categorical: 15–23, 25–34, 35–44, 45–54, and 55–64).
bOnly variables with relations with statistical significance shown.
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Table 4. Prevalence of diabetes and relation with other factors by gender (Caxito, 2016)
Associated factor
All participants
(n = 2 348)
Female 
(n = 1 220)
Male 
(n = 1 128)
Prevalence
% (95% CI)*
Prevalence
% (95% CI)*
Adjusted ORa,b
(95% CI)*
Prevalence
% (95% CI)*
Adjusted ORa,b
(95% CI)*
Total 9.2 (8.1–10.4) 8.9 (7.4–10.6) 1 9.6 (8.0–11.4) 1.4 (1.0–1.8)
Age (years)
15–24 4.4 (3.2–6.0) 4.4 (2.7–7.0) 1 4.4 (2.9–6.6) 1
25–34 5.6 (4.0–7.7) 3.2 (1.8–5.9) 0.8 (0.3–1.7) 8.0 (5.4–11.6) 1.9 (1.0–3.5)
35–44 13.2 (10.2–17.0) 12.7 (9.0–17.7) 3.3 (1.7–6.2) 13.9 (9.3–20.3) 3.4 (1.8–6.5)
45–54 19.3 (15.2–24.2) 17.6 (12.9–23.7) 4.8 (2.6–9.0) 22.2 (15.4–30.9) 6.2 (3.3–11.6)
55–64 17.2 (12.8–22.8) 15.5 (10.3–22.7) 4.0 (2.0–8.0) 20.7 (13.5–30.4) 5.6 (2.8–11.0)
Residence
Urban 9.8 (8.5–11.2) 9.2 (7.5–11.1) 1.6 (0.9–2.8) 10.4 (8.6–12.6) 2.6 (1.4–4.9)
Rural 6.8 (4.8–9.5) 7.4 (4.7–11.6) 1 6.0 (3.6–10.1) 1
Education (years completed)
None 11.5 (7.9–16.5) 11.9 (8.1-17.1) – 6.7 (1.2-29.8) –
1–4 11.7 (9.2–14.6) 10.0 (7.5-13.3) – 17.2 (11.5-24.9) –
5–9 8.3 (6.7–10.1) 7.1 (5.1–9.9) – 9.0 (6.9–11.6) –
> 10 7.7 (5.9–10.2) 6.2 (3.4–11.1) – 8.3 (6.1–11.3) –
BMI class (kg/m2)
 Underweight (< 18.5) 7.5 (4.9–11.4) 4.0 (1.7–9.0) 1 10.7 (6.6–16.9) 1
 Normal (18.5–24.9) 7.8 (6.6–9.2) 7.7 (5.9–9.9) 2.0 (0.7–5.1) 7.9 (6.3–9.9) 0.7 (0.4–1.2)
 Overweight (25.0–29.9) 12.4 (9.4–16.1) 10.4 (7.2–14.7) 2.4 (0.9–6.5) 16.5 (11.0–24.2) 1.1 (0.5–2.3)
Obese (≥ 30) 18.6 (13.4–25.4) 17.1 (11.5–24.5) 3.9 (1.4–11.1) 24.2 (12.8–41.0) 1.7 (0.6–4.5)
Abdominal obesity
No 7.0 (5.9–8.3) 3.5 (2.3–5.2) 1 7.5 (6.0–9.3) 1
Yes 15.9 (13.1–19.0) 8.8 (6.4–12.2) 1.5 (1.0–2.3) 24.3 (17.9–32.0) 2.3 (1.4–3.8)
Tobacco smoking
Non-current 8.8 (7.6–10.0) 8.6 (7.2–10.4) – 8.9 (7.3–10.8) –
Current 14.4 (9.6–21.0) 17.6 (8.3–33.5) – 13.3 (8.2–20.8) –
Alcohol consumption
No consumption 8.9 (7.6–10.5) 8.7 (6.9–10.8) – 9.2 (7.2–11.7) –
Occasional (< 3 days per week) 10.5 (8.0–13.7) 10.1 (6.9–14.6) – 11.0 (7.4–16.1) –
Frequent (≥ 3 days per week) 8.8 (6.4–12.0) 8.3 (4.7–14.3) – 9.1 (6.2–13.0) –
*Post-stratification weights used as described in the methods section.
aAdjusted for age (categorical: 15–23, 25–34, 35–44, 45–54, and 55–64).
bOnly variables with relations with statistical significance shown.
Hypertensive (n = 431)
Aware (n = 209)
48.5% (95% CI 43.8–53.2)
Treated (n = 68)
32.5% (95% CI 26.6–39.2)
among the aware
15.8% (95% CI12.6–19.5)
among the hypertensive
Controlled (n = 39)
57.7% (95% CI 46.2–68.6)
among the treated
9.1% (95% CI 6.7–12.1)
among the hypertensive
Diabetic (n = 223)
Aware (n = 24)
10.8% (95% CI 7.3–15.5)
Treated (n = 10)
41.7% (95% CI 24.5–61.2)
among the aware
4.5% (95% CI 2.5–8.1)
among the diabetic
Controlled (n = 6)
60.0% (95% CI 31.3–83.2)
among the treated
2.7% (95% CI 1.2–5.7) 
among the diabetic
Hypercholesterolaemic (n = 71)
Aware (n = 3)
4.2% (95% CI 1.5–11.7)
Treated (n = 1)
33.3% (95% CI 6.1–7.9)
among the aware
1.4% (95% CI 0.3–7.6)
among the hypercholesterolaemic
Controlled (n = 1)
100% (95% CI 20.7–100)
among the treated
1.4% (95% CI 0.3–7.6)
among the hypercholesterolaemic
Post-stratification weights used as described in the methods section.
Fig. 1.  Frequencies, awareness, treatment and control of hypertension, diabetes and hypercholesterolaemia.
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Table 5. Prevalence of hypercholesterolaemia and relation with other factors by gender (Caxito, 2016)
Associated factor
All participants 
(n = 1 781)
Female 
(n = 978)
Male 
(n = 803)
Prevalence
% (95% CI)*
Prevalence
% (95% CI)*
Adjusted ORa,b
(95% CI)*
Prevalence
% (95% CI)*
Adjusted ORa,b
(95% CI)*
Total 4.0 (3.2–5.0) 5.6 (4.3–7.2) 2.3 (1.3–4.0) 2.0 (1.2–3.2) 1
Age (years)
15–24 0.7 (0.3–1.8) 1.1 (0.4–3.2) 1 0.3 (0.1–1.9) 1
25–34 2.5 (1.4–4.3) 2.8 (1.4–5.7) 2.6 (0.6–10.8) 2.5 (1.1–5.3) 5.0 (0.8–31.6)
35–44 3.6 (2.0–6.4) 5.4 (2.9–9.6) 5.2 (1.4–20.0) 0.9 (0.2–4.7) 2.1 (0.2–24.4)
45–54 9.4 (6.3–13.7) 10.8 (6.9–16.7) 11.9 (3.30–42.7) 5.7 (2.5–12.8) 13.7 (2.1–88.1)
55–64 11.4 (7.6–16.8) 15.4 (10.0–23.0) 17.2 (4.8–61.9) 4.5 (1.6–12.5) 9.0 (1.2–69.5)
Residence
Urban 3.9 (3.0–5.0) 5.6 (4.2–7.4) – 1.8 (1.0–3.2) –
Rural 4.2 (2.5–7.0) 5.3 (2.8–9.8) – 3.5 (1.5–7.9) –
Education (years completed)
None 10.8 (7.0–16.2) 10.7 (6.9–16.3) – 11.1 (2.0–43.5) –
1–4 5.7 (3.9–8.3) 6.4 (4.3–9.5) – 2.5 (0.7–8.8) –
5–9 2.6 (1.7–4.1) 3.3 (1.9–5.9) – 2.0 (1.0–3.9) –
>10 2.0 (1.0–3.7) 2.3 (0.8–6.5) – 1.9 (0.9–4.0) –
BMI class (kg/m2)
 Underweight (<18.5) 2.3 (0.9–5.7) 3.2 (1.1–9.1) – 1.2 (0.2–6.5) –
 Normal (18.5–24.9) 3.5 (2.6–4.7) 5.1 (3.6–7.3) – 1.9 (1.1–3.3) –
 Overweight (25.0–29.9) 5.3 (3.3–8.3) 6.0 (3.6–10.1) – 3.8 (1.5–9.3) –
Obese (≥ 30) 6.7 (3.5–12.2) 8.6 (4.6–15.5) – –a –
Abdominal obesity
No 2.4 (1.7–3.4) 3.5 (2.3–5.2) – 1.5 (0.8–2.7) –
Yes 8.1 (6.0–10.9) 8.8 (6.4–12.2) – 5.9 (2.9–11.6) –
Tobacco smoking
Non-current 3.7 (2.9–4.8) 5.1 (3.9–6.7) – 2.0 (1.2–3.3) –
Current 6.4 (3.1–12.6) 17.9 (7.9–35.6) – 2.5 (0.7–8.6) –
Alcohol consumption
No consumption 4.3 (3.2–5.6) 5.7 (4.2–7.7) – 2.2 (1.2–4.1) –
Occasional (< 3 days per week) 2.7 (1.4–5.0) 4.6 (2.5–8.6) – –c –
Frequent (≥ 3 days per week) 3.9 (2.2–6.7) 5.6 (2.6–11.6) – 2.5 (1.1–5.7) –
*Post-stratification weights used as described in the methods section.
aAdjusted for age (categorical: 15–23, 25–34, 35–44, 45–54, and 55–64).
bOnly variables with relations with statistical significance shown.
cNo cases in this category.
Table 6. Awareness, treatment and control rates of hypertension by gender (Caxito, 2016)
Awareness Treatment Control
All (n = 209) Female (n = 131) Male (n = 78) All (n = 68) Female (n = 41) Male (n = 27) All (n = 39) Female (n = 25) Male (n = 14)
% (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
Education (years 
completed)
none 21.5 
(16.5–27.6)
34.4 
(26.8–42.8)
0 17.6 
(10.4–28.4)
26.8 
(15.7–41.9)
3.7 
(0.7–18.3)
10.3
(4.1–23.6)
16.0 
(6.4–34.7)
0
1–4 31.1 
(25.2–37.7)
40.5 
(32.4–49.0)
15.4 
(9.0–25.0)
27.9 
(18.7–39.6)
39.0 
(25.7–54.3)
11.1 
(3.9–28.1)
25.6 
(14.6–41.1)
40.0 
(23.4–59.3)
0
5–9 28.2 
(22.6–34.7)
22.1 
(15.9–30.0)
38.5 
(28.4–49.6)
29.4 
(19.9–41.1)
26.8 
(15.7–41.9)
33.3 
(18.6–52.2)
33.3 
(20.6–49.0)
36.0 
(20.2–55.5)
28.6 
(11.7–54.6)
> 10 19.1 
(14.4–25.0)
3.1 
(1.2–7.6)
46.2 
(35.5–57.1)
25.0 
(16.2–36.4)
7.3 
(2.5–19.4)
51.9 
(34.0–69.3)
30.8 
(18.6–46.4)
8.0 
(2.2–25.0)
71.4 
(45.4–88.3)
Age (years)
15–24 2.9 
(1.3–6.1)
0.8 
(0.1–4.2)
6.4 
(2.8–14.1)
1.5 
(0.3–7.9)
2.4 
(0.4–12.6)
0 2.6 
(0.5–13.2)
4.0 
(0.7–19.5)
0
25–34 16.7 
(12.3–22.4)
12.2 
(7.7–18.9)
24.4 
(16.2–34.9)
26.5 
(17.4–38.0)
24.4 
(13.8–39.3)
29.6 
(15.9–48.5)
33.3 
(20.6–49.0)
32.0 
(17.2–51.6)
35.7 
(16.3–61.2)
35–44 19.6 
(14.8–25.5)
19.1 
(13.3–26.7)
20.5 
(13.0–30.8)
20.6 
(12.7–31.6)
19.5 
(10.2–34.0)
22.2 (
10.6–40.8)
25.6 
(14.6–41.1)
24.0 
(11.5–43.4)
28.6 
(11.7–54.6)
45–54 31.1 
(25.2–37.7)
37.4 
(29.6–45.9)
20.5 
(13.0–30.8)
23.5 
(15.0–34.9)
26.8 
(15.7–41.9)
18.5 
(8.2–36.7)
17.9 
(9.0–32.7)
20.0 
(8.9–39.1)
14.3 
(4.0–39.9)
55–64 29.7 
(23.9–36.2)
30.5 
(23.3–38.9)
19.4 
(19.4–39.0)
27.9 
(18.7–39.6)
26.8 
(15.7–41.9)
29.6 
(15.9–48.5)
20.5 
(10.8–35.5)
20.0 
(8.9–39.1)
21.4 
(7.6–47.6)
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among women (66.7%; 95% CI: 20.8–93.9), older age groups 
and higher education levels (Table 8). The treatment rate of 
all conditions was more prevalent in the older age groups and 
higher education levels, but the control rate was more frequent 
in younger participants.
Among the individuals who were aware of any of the 
three conditions, the advice most often given by healthcare 
professionals to follow non-pharmacological approaches for 
the management of cardiovascular risk factors was a change 
in dietary habits, with a decrease in salt and fat intake, and 
increased fruit and vegetable intake (Table 9). 
Discussion 
The prevalence of hypertension among participants in the range 
of 15 to 64 years old was 18.0%. This value rose to 26.6% among 
participants aged 25 to 64 years, which is slightly higher than 
those previously described for Angola over the last eight years,14-
15 particularly a study conducted in the same region in 2010,16 
and the WHO age-standardised (25 to 64 years old) estimated 
hypertension prevalence for 2014 in Angola of 23.9% (95% CI: 
16.3–31.1).1 More recently, a cross-sectional study conducted in 
Uganda, South Africa, Tanzania and Nigeria encountered an 
overall age-standardised prevalence of hypertension of 25.9%.24 
The estimated 9.2% prevalence of diabetes (9.8% in urban 
and 6.8% in rural areas) was higher than previous reports from 
Angola of 5.7% among an urban population (aged 20 to 72 
years) in 2010,15 and 2.8% for a rural community (aged 30 to 
69 years) in 2009.17 The value of 9.8% estimated in individuals 
older than 18 years is in the middle range of prevalence levels 
encountered in STEPS surveys, with values from 3.0% in Benin 
to 22.5% in Niger.25,26 This value also falls within the confidence 
intervals of the WHO estimate of 12.1% (95% CI: 5.6–18.9) for 
increased blood glucose levels in those over 18 years in Angola 
for 2014.1 
This rise in diabetes is aligned with the global tendency for 
this disease, which has increased faster in LMIC than in high-
income countries since 1980.27 Since the end of the Angolan 
civil war in 2002, the population has been increasing and ageing. 
This, together with changes in food habits and the urbanisation 
process, may have led to the increased prevalence of diabetes in 
this region.
The prevalence of  hypercholesterolaemia (5.3% among 
participants 25 and 64 years old) in this study was lower than 
that found in a previous study in Luanda among an older urban 
population.15 However, this value falls within a wide range of 
values from several STEPS surveys measuring the prevalence 
of total cholesterol, from 2.1% in Mozambique to 26.0% in 
Tanzania.25,26 This prevalence may also be tied to the ageing 
population and changes in dietary habits that most African 
countries are currently facing.28 There is a lack of solid knowledge 
regarding the prevalence levels of hypercholesterolaemia in 
Africa, mainly owing to the difficulties in determining values of 
blood cholesterol in African communities because of the high 
cost of laboratory tests. This situation presents a challenge when 
comparing research results. 
As described in other studies worldwide, the clustering of risk 
factors helps to explain the known impacts of age, education 
and obesity on the occurrence of hypertension, diabetes and 
hypercholesterolaemia. The prevalence of these three conditions 
was higher among individuals with less education, and increased 
with age and BMI. 
Obesity represents a major concern as a risk factor for 
CVD and NCDs in general, and is connected with the current 
nutritional transition in Africa, with a shift in the composition 
and structure of diets traditionally low in fat and high in 
unrefined carbohydrates toward higher intakes of  refined 
carbohydrates, added sugars, fats and animal-source foods.28 This 
Table 9. Non-pharmacological advice by health professionals  
to aware participants (Caxito, 2016)
Hypertension 
(n = 209)
Diabetes 
(n = 24)
Hypercholes-
terolaemia 
(n = 3)
Advice % (95% CI) % (95% CI)* % (95% CI)*
Reduce salt in your diet 78.5 (72.4–83.5) 100.0 100.0
Reduce fat in your diet 61.7 (55.0–68.0) 91.7 66.7
Eat at least five servings of fruit and/
or vegetables each day 58.4 (51.6–64.8) 70.8 66.7
Reduce or stop alchool consumption 51.2 (44.5–57.9) 83.3 33.3
Start or do more physical activity 34.4 (28.3–41.1) 75.0 66.7
Quit using tobacco or don’t start 31.1 (25.2–37.7) 45.8 0
Maintain a healthy body weight or 
lose weight 30.1 (24.3-36.7) 75.0 66.7
*Due to the small sample size, the 95% CI was not determined.
Table 7. Awareness, treatment and control rates of diabetes by gender 
(Caxito, 2016)
Awareness Treatment Control
All 
(n = 24)
%
Female 
(n = 10)
%
Male 
(n = 14)
%
All 
(n = 10)
%
Female 
(n = 6)
%
Male 
(n = 4)
%
All 
(n = 6)
%
Female 
(n = 5)
%
Male 
(n = 1)
%
Education 
(years 
completed)
None 12.5 30.0 0.0 20.0 33.3 0 16.7 20.0 0
1–4 4.2 10.0 0.0 10.0 16.7 0 16.7 20.0 0
5–9 33.3 30.0 35.7 50.0 33.3 75.0 50.0 40.0 100.0
> 10 50.0 30.0 64.3 20.0 16.7 25.5 16.7 20.0 0
Age (years)
15–24 8.3 20.0 0.0 20.0 33.3 0 33.3 40.0 0
25–34 12.5 10.0 14.3 10.0 16.7 0 16.7 20.0 0
35–44 20.8 10.0 28.6 20.0 16.7 25.5 16.7 20.0 0
45–54 25.0 20.0 28.6 10.0 16.7 0 0 0 0
55–64 33.3 40.0 28.6 40.0 16.7 75.0 33.3 20.0 100.0
Table 8. Awareness, treatment and control rates of  
hypercholesterolemia by gender (Caxito, 2016)
Awareness Treatment Control
All 
(n = 3)
%
Female 
(n = 2)
%
Male 
(n = 1)
%
All 
(n = 1)
%
Female 
(n = 1)
%
Male 
(n = 0)
%
All 
(n = 1)
%
Female 
(n = 1)
%
Male 
(n = 0)
%
Education 
(years 
completed)
None 0 0 0 0 0 0 0 0 0
1–4 33.3 50.0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 0 0 0 0
> 10 66.6 50.0 100.0 100.0 100.0 0 100.0 100.0 0
Age (years)
15–24 0 0 0 0 0 0 0 0 0
25–34 0 0 0 0 0 0 0 0 0
35–44 33.3 50.0 0 100.0 100.0 0 100.0 100.0 0
45–54 66.6 50.0 100.0 0 0 0 0 0 0
55–64 0 0 0 0 0 0 0 0 0
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shift may have had an impact on the rise in incidence of diabetes 
over the past decades, revealed in recent literature reviews,29-31 as 
well as a WHO estimation of the rise in median prevalence of 
elevated total cholesterol for this region.2 
Similar to this nutritional transition, the process of 
urbanisation underway in the region must be taken into 
consideration for future interventions. Living in an urban area 
has been associated with a two-fold increase in the prevalence of 
diabetes among this population, as described in other studies.1,29-31 
Information regarding the awareness, treatment and control 
rates for the three conditions investigated is scarce for the 
African continent, except for hypertension; there are also some 
available data with regard to diabetes. Our findings for awareness 
of hypertension were higher than those calculated in 2010 for 
Africa, with an estimated 33.7% pooled awareness rate.32 Current 
values for awareness, treatment and control of hypertension are 
higher than in 2011 in the same population; results for awareness 
were 21.6% (95% CI: 17.0–26.9) in 2011 and 48.5% in the present 
study. Values for participants who were aware of their condition 
and on pharmacological treatment (13.9%, 95% CI: 5.9–29.1) 
increased to 32.5%; approximately one-third of participants 
were controlled in 2011 and more than half were controlled in 
our study. This may have resulted from the positive effect of 
identification of hypertensive individuals and medical follow up 
after the first survey in 2011. 
Nonetheless, the levels of awareness about hypertensive status 
are still low, a situation common in Africa,33 with levels much 
lower than those in North America and Europe.34 A similar 
framework exists for diabetes awareness in Africa, with fewer 
than 50% of participants in one study aware of their condition.29 
No data were found for awareness of total cholesterol levels. 
The lack of primary healthcare facilities in this region, 
especially in rural areas, makes the low levels of previous 
measurements plausible. Furthermore, the current training of 
Angolan health professionals and the availability of clinical 
equipment are still focused on infectious diseases, not considering 
CVD a priority. Therefore initiatives promoting the awareness 
of CVD are lacking in the region, and proper monitoring of 
patients’ conditions does not occur. 
Moreover, the information available to the population is 
not enough to convince patients to take lifelong medication in 
order to treat a condition, which is usually asymptomatic. Only 
one-third of participants with any of these conditions had access 
to treatment, which demonstrates the inadequacy of the region’s 
health system to help patients manage risk factors. Economic 
difficulties and the lack of drugs to address CVD may also help 
explain the low levels of treatment and control found.
Nevertheless, a positive note should be made as to the 
number of patients who had controlled levels of blood pressure, 
blood sugar and cholesterolaemia in this specific population. 
Considering that they were younger and better educated, they 
could have had easier access to drugs and health facilities. Also 
noteworthy, in the absence of access to drugs, physicians’ advice 
in most cases is to adopt non-pharmacological approaches to 
reducing modifiable risk factors, mainly associated with diet.
Strengths and limitations of the study
Our study findings should be interpreted cautiously because 
the Dande-HDSS was developed as a district-level surveillance 
system in an urban and rural setting and is therefore not 
representative of the demographic structure of the country. In 
addition, age groups over 65 years old (known for higher rates 
of the conditions studied) were not considered owing to their low 
representation in the general structure of the population (3.6% 
of the Dande-HDSS population),18 which is a common practice 
for surveys conducted in sub-Saharan Africa.
Internal migration and the geographical isolation of some 
hamlets within the Dande-HDSS, together with the fact that 
working individuals were unavailable during the daytime,17 were 
reflected in the sampling definition, with a 30% non-participation 
rate. The distribution of non-respondents was uneven, with a 
higher proportion of younger people and men (data not shown). 
This may have caused instability in the estimates in some strata.
Participants were requested not to eat anything eight hours 
before participating in the study; however, it was difficult to 
measure adherence to this request, which adds uncertainty to 
the measures of blood glucose and cholesterol. We used dry 
chemistry devices to measure glycaemia and cholesterolaemia, 
but owing to high temperatures and humidity during field 
surveys, data collection was not possible in some cases, causing a 
higher number of missing data than expected.
Due to the many variables covered in the survey and to 
avoid drop-out of participants in future rounds, additional 
questions relating to awareness, pharmacological treatments 
and non-pharmacological approaches were conducted in a more 
detailed form in individual follow-up visitations. These are not 
dealt with extensively in this article. Also the low number of 
aware individuals and consequently under-treatment limited the 
statistical analysis of data regarding these aspects.
It is therefore not possible to extrapolate our findings to a 
larger population at country level. However, this study reveals 
new data about the prevalence, awareness, treatment and control 
of diabetes and hypercholesterolaemia, and it is the most 
comprehensive community-based study conducted to date in 
Angola.
Future direction
The inclusion of younger participants (15 to 24 years) allows 
a better representation of the demographic structure of the 
country and creates a baseline for future surveys. The emphasis 
for future interventions should be aimed at younger populations 
in which the prevalence of major risk factors is still low, so as to 
make a difference in the long term.
In all LMIC, NCDs are the leading cause of death and 
disability, killing nearly eight million people under 60 years 
old in 2013.25 Over the past decade, the focus of assistance in 
these countries has primarily addressed maternal and child 
health and infectious diseases. Without setting these aside, there 
is an opportunity to use structures that are already in place, 
to maximise resources. The international community should 
consider expanding the mandate of current programmes to 
include outcome-orientated measures for improving general 
health and lifestyles. 
Many of the methods of NCD prevention, management and 
treatment, which are responsible for the decline in some of these 
diseases in high-income countries, are inexpensive but are not 
widely used in LMIC. These methods could be implemented 
through established global health strategies, such as increased 
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use of low-cost drugs,35 and improved access to NCD services 
for young adults and people with low educational attainment.36
Conclusions
This report reinforces the available data for the main CVD 
risk factors in Angola and helps to build the basis for further 
prospective studies, especially among the younger group in 
this region. We provide the first evidence that hypertension 
prevalence is rising, together with diabetes, when compared with 
previous studies in the region. 
Despite being a growing economy, Angola’s primary health 
system may not be currently able to provide an adequate answer 
to the changing health needs of this population. A gradual 
shift from infectious diseases to NCDs is underway and this 
puts additional stress on the reinforcement of primary care 
intervention in the region.
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